Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 17/20 | 1.00 |
| ▸ | INSR | P06213 | 8/20 | 1.00 |
| ▸ | IGF1R | P08069 | 7/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 2/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | ERN1 | O75460 | 2/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | HCK | P08631 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tae-684 SCHEMBL29641017 | 1.00 | ALK (1.00) | ALKINSRIGF1REGFRFGFR1 | |
| SCHEMBL12780522 | 0.95 | ALK (1.00) | ALKINSRIGF1REGFRFGFR1 | |
| SCHEMBL12892781 | 0.94 | ALK (0.91) | ALKINSRIGF1REGFRFGFR1 | |
| SCHEMBL12781735 | 0.94 | ALK (0.88) | ALKINSRIGF1REGFRFGFR1 | |
| SCHEMBL18843559 | 0.93 | ALK (0.87) | ALKINSRIGF1REGFRFGFR1 | |
| SCHEMBL24301100 | 0.93 | ALK (0.87) | ALKINSRIGF1REGFRFGFR1 | |
| SCHEMBL4098937 | 0.92 | ALK (0.85) | ALKINSRIGF1REGFRFGFR1 | |
| SCHEMBL22493267 | 0.92 | ALK (0.85) | ALKINSRIGF1REGFRFGFR1 | |
| SCHEMBL21478104 | 0.92 | ALK (0.87) | ALKINSRIGF1REGFRFGFR1 | |
| SCHEMBL15217778 | 0.91 | ALK (0.84) | ALKINSRIGF1REGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522873-B2 | ALK and NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | claimed |
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | claimed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | claimed |
| US-20250146076-A1 | ALK GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-05-08 | — | — | US | claimed |
| WO-2025096061-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250129430-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | VeraVerse Co., Ltd. (KR) | 2025-04-24 | — | — | US | claimed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | claimed |
| WO-2025054386-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | claimed |
| US-20150184161-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2015-07-02 | — | — | US | claimed |
| WO-2014203152-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2014-12-24 | — | — | WO | claimed |
| EP-2116553-B1 | EML4-ALK fusion gene | ASTELLAS PHARMA INC (JP) | 2014-07-30 | — | — | EP | claimed |
| US-20130158095-A1 | EML4-ALK FUSION GENE | CUREGENE K.K. (JP) | 2013-06-20 | — | — | US | claimed |
| US-20110230545-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | claimed |
| US-20100240673-A1 | EML4-ALK Fusion Gene | ASTELLAS PHARMA INC. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2116553-A1 | EML4-ALK fusion gene | Astellas Pharma Inc. (JP) | 2009-11-11 | — | — | EP | claimed |
| US-20090099193-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2009-04-16 | — | — | US | claimed |
| EP-1914240-A1 | EML4-ALK fusion gene | Astellas Pharma Inc. (JP) | 2008-04-23 | — | — | EP | claimed |
| US-20080090776-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2008-04-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | SYK, BTK, G6PD | ALK 1620/4885INSR 1946/4885IGF1R 1255/4885 |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | RCC2, GLS, VHL | ALK 2234/4885INSR 2422/4885IGF1R 1774/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | ALK 171/4885INSR 2259/4885IGF1R 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.